Zosano Pharma Corporation (ZSAN): Price and Financial Metrics
GET POWR RATINGS... FREE!
ZSAN POWR Grades
- ZSAN scores best on the Growth dimension, with a Growth rank ahead of 82.49% of US stocks.
- The strongest trend for ZSAN is in Stability, which has been heading up over the past 164 days.
- ZSAN's current lowest rank is in the Quality metric (where it is better than 1% of US stocks).
ZSAN Stock Summary
- Zosano Pharma Corp's capital turnover -- a measure of revenue relative to shareholder's equity -- is better than merely 8.13% of US listed stocks.
- ZSAN's price/sales ratio is 55.84; that's higher than the P/S ratio of 96.61% of US stocks.
- Revenue growth over the past 12 months for Zosano Pharma Corp comes in at 91.29%, a number that bests 92.61% of the US stocks we're tracking.
- Stocks with similar financial metrics, market capitalization, and price volatility to Zosano Pharma Corp are GNCA, INFI, ATNM, ARAV, and VBLT.
- ZSAN's SEC filings can be seen here. And to visit Zosano Pharma Corp's official web site, go to www.zosanopharma.com.
ZSAN Valuation Summary
- In comparison to the median Healthcare stock, ZSAN's price/earnings ratio is 107.12% lower, now standing at -2.6.
- Over the past 80 months, ZSAN's price/sales ratio has gone up 77.2.
- Over the past 80 months, ZSAN's price/sales ratio has gone up 77.2.
Below are key valuation metrics over time for ZSAN.
| Stock | Date | P/S | P/B | P/E | EV/EBIT |
|---|---|---|---|---|---|
| ZSAN | 2021-08-31 | 121.9 | 1.9 | -2.6 | -2.3 |
| ZSAN | 2021-08-30 | 116.4 | 1.8 | -2.5 | -2.2 |
| ZSAN | 2021-08-27 | 120.6 | 1.9 | -2.6 | -2.3 |
| ZSAN | 2021-08-26 | 120.4 | 1.9 | -2.6 | -2.3 |
| ZSAN | 2021-08-25 | 118.1 | 1.8 | -2.5 | -2.3 |
| ZSAN | 2021-08-24 | 116.1 | 1.8 | -2.5 | -2.2 |
ZSAN Growth Metrics
- Its 2 year net income to common stockholders growth rate is now at -21.57%.
- The 4 year cash and equivalents growth rate now stands at 188.24%.
- Its 4 year net income to common stockholders growth rate is now at -15.31%.
The table below shows ZSAN's growth in key financial areas (numbers in millions of US dollars).
| Date | Revenue | Operating Cash Flow | Net Income to Common Stock |
|---|---|---|---|
| 2021-09-30 | 0.922 | -28.041 | -31.052 |
| 2021-06-30 | 0.67 | -30.719 | -31.071 |
| 2021-03-31 | 0.482 | -30.734 | -32.822 |
| 2020-12-31 | 0.224 | -31.718 | -33.369 |
| 2020-09-30 | 0 | -32.903 | -34.211 |
| 2020-06-30 | 0 | -32.646 | -35.387 |
ZSAN's Quality Factors
The “Quality” component of the POWR Ratings focuses on 31 different factors of a companies fundamentals and operational strength. Here are some key insights as we drill into the specifics of these quality attributes.- ZSAN has a Quality Grade of F, ranking ahead of 0.35% of graded US stocks.
- ZSAN's asset turnover comes in at 0.01 -- ranking 391st of 682 Pharmaceutical Products stocks.
- HGEN, ATRA, and ARMP are the stocks whose asset turnover ratios are most correlated with ZSAN.
The table below shows ZSAN's key quality metrics over time.
| Period | Asset Turnover | Gross Margin | ROIC |
|---|---|---|---|
| 2021-06-30 | 0.010 | 0.201 | -0.773 |
| 2021-03-31 | 0.007 | 0.309 | -0.821 |
| 2020-12-31 | 0.004 | 0.237 | -0.872 |
| 2020-09-30 | 0.000 | NA | -0.932 |
| 2020-06-30 | 0.000 | NA | -1.021 |
| 2020-03-31 | 0.000 | NA | -1.122 |
ZSAN Price Target
For more insight on analysts targets of ZSAN, see our ZSAN price target page. And for a list of of all stocks sorted by upside potential based on analyst target price, see our Top Price Target page.
| Average Price Target | $2.17 | Average Broker Recommendation | 1.33 (Strong Buy) |
ZSAN Stock Price Chart Interactive Chart >
ZSAN Price/Volume Stats
| Current price | $0.42 | 52-week high | $3.06 |
| Prev. close | $0.43 | 52-week low | $0.41 |
| Day low | $0.41 | Volume | 831,093 |
| Day high | $0.45 | Avg. volume | 2,102,384 |
| 50-day MA | $0.54 | Dividend yield | N/A |
| 200-day MA | $0.71 | Market Cap | 49.71M |
Zosano Pharma Corporation (ZSAN) Company Bio
Zosano Pharma Corporation provides biopharmaceutical products and services. The Company specializes in biopharmaceuticals, peptides, small water soluble molecules, monoclonal antibodies, and vaccines for the treatment of severe osteoporosis.
Latest ZSAN News From Around the Web
Below are the latest news stories about Zosano Pharma Corp that investors may wish to consider to help them evaluate ZSAN as an investment opportunity.
Morgan Jess S & Co Inc Buys Wells Fargo, PowerShares QQQ Trust Ser 1, NVIDIA Corp, Sells ...Investment company Morgan Jess S & Co Inc (Current Portfolio) buys Wells Fargo, PowerShares QQQ Trust Ser 1, NVIDIA Corp, Microsoft Corp, Vanguard Total International Stock, sells Amgen Inc during the 3-months ended 2021Q4, according to the most recent filings of the investment company, Morgan Jess S & Co Inc. |
CORRECTION - Zosano Pharma Announces Publication of Clinical Data Demonstrating Comparable Immunogenicity of a Trivalent Influenza Vaccine Formulated on its Transdermal Microneedle System Versus an Intramuscular Injection of the Vaccine at a Higher Dose—Data published in the Journal of Vaccines and Immunology—FREMONT, Calif., Jan. 05, 2022 (GLOBE NEWSWIRE) -- In a press release published under the same headline today by Zosano Pharma Corporation (Nasdaq:ZSAN), a measurement was incorrectly stated as grams, not micrograms. The measurements of the vaccine should have been 10μg and 15μg, not 10 g and 15 g as previously stated. The corrected release follows: Zosano Pharma Corporation (NASDAQ:ZSAN), a clinical-stage biopharmaceutical company, today |
Zosano Pharma Announces Publication Of Early Data On Influenza VaccineZosano Pharma Corporation (NASDAQ: ZSAN) announced the publication of Phase 1 trial data of influenza vaccine in the Journal of Vaccines and Immunology. The data demonstrated that a low dose of a trivalent influenza vaccine administered via its transdermal microneedle system produced antibody levels and was generally well tolerated. The Company noted that a lower dose of an influenza vaccine produced antibody levels similar to an intramuscular injection of the same vaccine at a higher dose. The |
Zosano Pharma Announces Publication of Clinical Data Demonstrating Comparable Immunogenicity of a Trivalent Influenza Vaccine Formulated on its Transdermal Microneedle System Versus an Intramuscular Injection of the Vaccine at a Higher Dose—Data published in the Journal of Vaccines and Immunology—FREMONT, Calif., Jan. 05, 2022 (GLOBE NEWSWIRE) -- Zosano Pharma Corporation (NASDAQ:ZSAN), a clinical-stage biopharmaceutical company, today announced the publication of Phase 1 clinical trial data in an article titled, “Immunogenicity and Safety of Inactivated Influenza Split-Virion Vaccine Administered via a Transdermal Microneedle System” in the Journal of Vaccines and Immunology. The data demonstrated that a low dose of a trivalent i |
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on MondayWelcome back to a new year, investor! |
ZSAN Price Returns
| 1-mo | -12.95% |
| 3-mo | -30.57% |
| 6-mo | -44.74% |
| 1-year | -55.09% |
| 3-year | -82.64% |
| 5-year | -98.16% |
| YTD | -10.64% |
| 2021 | -10.83% |
| 2020 | -65.32% |
| 2019 | -28.30% |
| 2018 | -79.62% |
| 2017 | -33.33% |
Loading social stream, please wait...